(1/4) Artificial intelligence may be one of the most important tools we have in the global fight against AMR, which now contributes to 4.5 million deaths each year.
Comments
Log in with your Bluesky account to leave a comment
(2/4) AI allow us to probe DNA and proteins from both extinct and living organisms for new and optimal antibiotics far more efficiently than any human-led research team ever could.
(3/4) But the market for antibiotics is broken and private investment is sorely lacking, making it exceedingly difficult to advance even the most-promising candidates through clinical development and to patients.
(4/4)It was illuminating to think through these challenges with Henry Skinner of the @amractionfund.bsky.social and Dr. Christina Yen in a new paper for @bulletinatomic.bsky.social. As we note, to fully reap the benefits of AI, antibiotic policies and market dynamics must evolve alongside AI.
Comments